Abstract
RNA interference (RNAi) is a mechanism in which double-stranded (ds) RNA acts as a guide to sequence-specifically suppress gene expression. To achieve targeted knock-downs of gene function in mammalian cells, in vitro synthesised small interfering RNAs (siRNAs) can be introduced transiently into cells or, for more stable suppression by RNAi, various vector strategies can be employed to achieve prolonged in vivo synthesis of targeting RNA sequences. RNAi, beyond being a powerful experimental tool, has been widely promoted as a future gene-targeted therapeutic strategy of exquisite specificity. In the context of cancer, in which mutation, over-expression and de-novo acquisition of tumour-promoting genes are of central importance to the pathology, multiple molecular targets have been proposed for RNAi-based therapies. In this review, we will summarise what is known about the biology of RNAi in mammalian cells, outline the various expression and delivery strategies that have been developed, and discuss the features of possible therapeutic gene targets. We will also highlight the present technical limitations of RNAi that will need to be addressed if it is to be developed therapeutically, including the important issues of effective delivery and the potential for development of tumour resistance.
Keywords: cancer, rnai, rna interference, therapy, tumor
Current Cancer Therapy Reviews
Title: RNA Interference: A New Targeted Tumour Therapy?
Volume: 1 Issue: 1
Author(s): Jane M.E. Withey and Mark R. Crompton
Affiliation:
Keywords: cancer, rnai, rna interference, therapy, tumor
Abstract: RNA interference (RNAi) is a mechanism in which double-stranded (ds) RNA acts as a guide to sequence-specifically suppress gene expression. To achieve targeted knock-downs of gene function in mammalian cells, in vitro synthesised small interfering RNAs (siRNAs) can be introduced transiently into cells or, for more stable suppression by RNAi, various vector strategies can be employed to achieve prolonged in vivo synthesis of targeting RNA sequences. RNAi, beyond being a powerful experimental tool, has been widely promoted as a future gene-targeted therapeutic strategy of exquisite specificity. In the context of cancer, in which mutation, over-expression and de-novo acquisition of tumour-promoting genes are of central importance to the pathology, multiple molecular targets have been proposed for RNAi-based therapies. In this review, we will summarise what is known about the biology of RNAi in mammalian cells, outline the various expression and delivery strategies that have been developed, and discuss the features of possible therapeutic gene targets. We will also highlight the present technical limitations of RNAi that will need to be addressed if it is to be developed therapeutically, including the important issues of effective delivery and the potential for development of tumour resistance.
Export Options
About this article
Cite this article as:
Withey M.E. Jane and Crompton R. Mark, RNA Interference: A New Targeted Tumour Therapy?, Current Cancer Therapy Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573394052952447
DOI https://dx.doi.org/10.2174/1573394052952447 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiplatelet and Antileukocyte Effects of Cardiovascular,Immunomodulatory and Chemotherapeutic Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Palifermin in theManagement of Mucositis in Hematological Malignancies: Current Evidences and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance
Anti-Cancer Agents in Medicinal Chemistry Surface Plasmon Resonance Imaging (SPRI) Sensor for Cystatin Determination Based on Immobilized Papain
Protein & Peptide Letters Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics The Molecular Basis of Notch Signaling Regulation: A Complex Simplicity
Current Molecular Medicine Eph/Ephrin Membrane Proteins: A Mammalian Expression Vector pTIg- BOS-Fc Allowing Rapid Protein Purification
Protein & Peptide Letters Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry Potential Therapeutic Approaches for the Treatment of Acute Myeloid Leukemia with AML1-ETO Translocation
Current Cancer Drug Targets Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future
Current Topics in Medicinal Chemistry Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Cannabinoid Type 2 Receptor as a Target for Chronic - Pain
Mini-Reviews in Medicinal Chemistry